Clinical Trial Results of MRT-2359 - MRT-2359 combined with enzalutamide demonstrated a 100% PSA response rate in heavily pre-treated mCRPC patients with AR mutations[5, 38, 59] - Among the 4 patients with AR mutations, 2 patients showed PSA90 responses and 2 patients showed PSA50 responses[5, 38] - Two patients with AR mutations achieved RECIST partial responses (1 confirmed, 1 unconfirmed), and two had stable disease, resulting in a 100% disease control rate in the AR mutant population[5] - An overall disease control rate (DCR) of 64% was observed in 14 evaluable patients, including 5 patients without AR mutations who had stable disease[5, 59] Safety and Tolerability - The combination of MRT-2359 and enzalutamide was well-tolerated, with the most frequent adverse events (AEs) being mild or moderate manageable GI symptoms[5, 33, 59] - Treatment-related AEs occurring in >15% patients included fatigue (50%), diarrhea (45%), nausea (35%), arthralgia (30%), decreased appetite (30%), vomiting (30%), neutropenia (25%), and muscular weakness (20%)[31, 32] Future Plans - The company plans to initiate a signal-confirming 2-stage Phase 2 study (MODeFIRe-1) of MRT-2359 in combination with a 2nd generation AR inhibitor in 2026, targeting AR-mutated mCRPC[2, 56, 59] - Updated data from the Phase 1/2 study is expected to be presented at the ASCO Genitourinary Cancers Symposium in February 2026[59]

Investor Presentation September 30, 2025 CAUTIONARY STATEMENT This document is current as of September 30, 2025, except where otherwise stated. The information contained in this presentation is provided by Organigram Global Inc. ("Organigram" or the "Company") for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Organigram or other financial products. No part of this presentation shall form the basis or be reli ...

Efficacy Results - The Phase 2b REZOLVE-AA study evaluated rezpegaldesleukin (REZPEG) for alopecia areata [1, 19] - The study achieved statistical significance for both treatment arms after excluding 4 patients with major study eligibility violations [36] - The mean percentage change in SALT score from baseline to week 36 was -30% in the REZPEG arms versus -6% in the placebo arm (p<0.05), after excluding 4 patients with major study eligibility violations [92] - 42% of REZPEG-treated patients achieved a best reduction in SALT score of 30% or greater [47] - 36% of REZPEG-treated patients achieved a best reduction in SALT score of 50% or greater [47] - 17% of REZPEG-treated patients achieved a best reduction in SALT score of 75% or greater [47] Safety and Tolerability - The study showed a consistent safety profile with previously reported studies, with nearly all adverse events (AEs) being mild to moderate in severity and self-resolved [31] - The discontinuation rate due to AEs was low at 1.4% for REZPEG-exposed patients [31] - The placebo-adjusted injection site reaction (ISR) rate was consistent with prior studies, with 87% being mild in severity [31] Market and Strategic Implications - The data supports a first-in-class Treg mechanism of action with fast onset of action in moderate-to-severe patients [9] - 54% of physicians report they would try patients on alternate therapies for AA before prescribing JAKi [10] - G7 market size for Alopecia Areata is projected to reach $4 billion by 2033 [7]

DXd ADC Portfolio & Approvals - Daiichi Sankyo's DXd ADC technology received 3 World ADC Awards in 2025[21, 23, 25] - ENHERTU has achieved 15 new regulatory approvals across 15 countries/regions and 94 extension approvals across 45 countries/regions as of CY2025[31] - DATROWAY received 1 accelerated approval for TROPION-Lung05 based on Breakthrough Therapy Designation (BTD)[31] - I-DXd in SCLC and R-DXd in PROC received BTDs, totaling 13 BTDs for the DXd ADC portfolio[31] Clinical Trial Results & Advancements - DESTINY-Breast11 (Neoadjuvant) demonstrated statistically significant and clinically meaningful improvement in pCR vs ddAC-THP in patients with high-risk HER2+ eBC[39, 41] - DESTINY-Breast05 (Post Neoadjuvant) showed a 53% reduction in the risk of invasive disease recurrence or death for T-DXd compared with T-DM1 in patients with HER2+ eBC[42, 44] - In TROPION-Breast02, DATROWAY demonstrated a statistically significant and clinically meaningful improvement of ~5 months in both mOS (23.7 vs 18.7 months) and mPFS vs chemotherapy (OS HR: 0.79)[46, 48] - DATROWAY achieved an ORR of 62% vs 293% for chemotherapy in TROPION-Breast02[50] Oncology Business Performance & Strategy - Daiichi Sankyo aims to deliver 900 Billion JPY in 5 years (FY2021 to 2025)[131] - ENHERTU delivered ¥5528 Billion in revenue in FY2024, with US and EU leading the way[134] - ENHERTU has treated 194000 patients globally[132, 134] - DATROWAY global net sales exceeded 10 Billion JPY in Q2 FY'25[157] Manufacturing and Supply - Daiichi Sankyo is expanding production capacity and enhancing capabilities to maximize supply volume for 5 DXd ADCs[190, 191] - The company is utilizing both in-house manufacturing and multiple CMOs to establish diversified manufacturing and supply routes[197]

OmniUltra Platform Overview - OmniUltra is the first and only transgenic chicken producing antibodies on a human framework with ultralong CDRH3s, similar to those found in cows[24] - Ultralong CDRH3s can reach binding pockets inaccessible to other antibodies, and can be cleaved to create Picobodies, the smallest functional antibody fragment[24] - OmniUltra is engineered for *in vivo* optimization, generating molecules pre-selected for function, affinity, and structural stability, potentially uncovering novel binding domains[27] - The platform leverages a transgenic chicken host to deliver biologically-optimized structured peptides, unlike phage display or other peptide discovery technologies[28] Competitive Advantages and Biological Intelligence - Antibodies generated *in vivo* are naturally optimized for specificity and developability[37] - The immune system in engineered transgenic animals creates optimized antibodies for human therapeutics, termed Biological Intelligence, increasing the efficiency and probability of success in therapeutic antibody discovery[37] - Greater evolutionary distance yields greater immunogenicity and more antibody diversity in chicken platforms[38] Epitope Coverage and Peptide Discovery - OmniUltra chickens are immunoresponsive to a variety of antigen targets[42] - Ultralong CDRH3 IgG clones bind to overlapping and novel epitopes[45] - OmniUltra can identify naturally-optimized peptide sequences that can be chemically synthesized as picobodies and retain antibody-like affinity and specificity to the immunized target[49] Market Opportunities and Expansion - The estimated total available commercial therapeutic market in 2034 is over $1 trillion, including peptides ($332 billion), bi-specifics ($460 billion), CAR-T ($224 billion), and radiopharma ($14 billion)[64] - Expansion into peptides provides an opportunity to drive service revenue and increases the potential audience of new partners by adding >130 peptide companies[66, 68]

POWERING FORWARD DECEMBER 15, 2025 – INVESTOR PRESENTATION 1 Cautionary Statement This document has been prepared by WSP Global Inc. ("WSP" or the "Corporation") solely for information purposes. Prospectus Information A final base shelf prospectus of WSP dated August 8, 2024, containing important information relating to the securities described in this document has been filed with the securities regulatory authorities in each of the provinces and territories of Canada. A copy of the final base shelf prospec ...

Investor Presentation Q3 Fiscal 2026 Safe Harbor Disclaimer This presentation contains "forward-looking statementsˮ within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Navan's anticipated total revenue, non-GAAP income (loss) from operations, and non-GAAP operating margin for the fiscal quarter and year ending January 31, 2026, the size of Navan's market opportunity, market trends, and the company's business strategy and plans. In s ...

Footprint Optimization - The company is shutting down three North American chlorovinyl plants and exiting the styrene business due to unfavorable market conditions and high costs[2, 5] - These closures are expected to improve annual EBITDA by approximately $100 million and generate free cash flow savings of around $175 million in 2026[2, 9] - The company anticipates one-time charges of about $415 million in 4Q'25, including a $357 million non-cash accelerated depreciation, amortization, and asset write-off charge[9] - The shutdown includes the following capacity reductions: 825 million lbs of Chlorine (11% of WLK global capacity), 910 million lbs of VCM (11% of WLK global capacity), 1,000 million lbs of PVC (15% of WLK global capacity), and 570 million lbs of Styrene (100% of WLK global capacity)[5] Profitability Improvement Plan - The company's Profitability Improvement Plan aims to restore PEM's Return on Investment to an appropriate level[4] - The plan is expected to generate approximately $600 million per year of EBITDA uplift starting in 2026, with each of the three pillars contributing around $200 million[9, 10, 12] - The footprint optimization efforts, including North American chlorovinyls and styrene closures, are projected to contribute $100 million to the $200 million total from Footprint Optimization[10] - The plan has an expected payback period of less than one year on the $58 million cash costs required for execution[2, 9]

FDA Approval Investor Call December 15, 2025 Forward Looking Statements The Presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Words such as ''aim,'' ''anticipate,'' ''assume,'' ''believe,'' ''contemplate,'' ''continue,'' ''could,'' ''design,'' ''due,'' ''estimate,'' ''expect,'' ''goal,'' ''intend,'' ''may,'' ''objective,'' ''plan,'' ''predict,'' ''positioned,'' ''potential,'' ''project,'' ''s ...

Biopharma Business Growth and Strategy - Fresenius' Biopharma business is rapidly scaling, with revenue increasing from €04 billion in 2022 to an estimated >€08 billion in 2025[23, 24] - The company aims to approximately double its Biopharma revenue by 2030, targeting a ~20% EBIT margin[42, 43] - The global biosimilars market is projected to grow sixfold by 2035, reaching >€180 billion[19, 48] Manufacturing and Cost Leadership - Fresenius is investing >€300 million over the next 5 years to expand Biopharma manufacturing capacity and drive growth[122] - The company's vertical integration strategy, particularly through mAbxience, provides a competitive advantage, covering ~75% of manufacturing costs[64] - Fresenius aims to increase internal Drug Substance (DS) manufacturing to >60% of total capacity required by 2030[130] Portfolio and R&D - Fresenius has a competitive portfolio and pipeline covering €200 billion in originator sales[82, 89] - The company targets 2+ molecules per year entering development through in-house R&D and strategic in-licensing[82, 88] - Fresenius' US tocilizumab biosimilar, Tyenne, has achieved a market share of ~18% as of September 2025[163] Commercial Excellence - Fresenius is expanding its commercial presence in the US, with revenue growth of >60% expected from 2024 to 2025[161] - The company is implementing a targeted go-to-market strategy, molecule by molecule, to optimize market access and contracting[151, 165] - Fresenius has a strong European core with direct sales in >20 markets and deep payer access[157]